About this Research Topic
Next-generation sequencing (NGS), also referred to as high-throughput sequencing, is a technology that allows simultaneous sequencing of millions of DNA or RNA sequences. NGS offers several advantages over traditional sequencing methods, like high throughput sample multiplexing, enhanced sensitivity in detecting low-frequency variants, faster turnaround time for handling high sample volumes, and lower cost. NGS has a wide spectrum of clinical applications and has seamlessly integrated into the realm of precision medicine.
The technology has been extensively employed in diagnosis, prognosis, and therapy selection across various domains, including constitutional disorders, oncology, and infectious diseases. Concurrently, an increasing amount of well curated clinical, genetic, and genomic data is being generated by NGS, further driving the development of precision medicine. Notably, the U.S. Food and Drug Administration (FDA) has recently introduced the guidelines for the design, development, and validation of NGS tests, and approved several NGS-based tests and targeted therapies.
In addition, the Centers for Medicare & Medicaid Services (CMS) has been monitoring the rapid innovation of NGS tests, ensuring comprehensive coverage for these NGS-based tests. These remarkable advancements have significantly increased the application of NGS into clinical settings.
Therefore, this research topic aims to gather the most-up-to-date developments in NGS technologies, bioinformatics pipeline for NGS data analysis, and their clinical applications. We welcome Original Research Articles, Reviews, Mini Reviews, Systematic Reviews, Perspectives, Commentaries, Data notes, and technical notes, but are not limited to the following:
• Newly developed NGS technologies in precision medicine
• Newly developed bioinformatics pipeline/programs for NGS data analysis
• Clinical applications of NGS in diagnosis, prognosis, and therapeutics of cancers, inherited diseases, infectious diseases and chronic diseases.
• Studies bridging the gap between NGS research and clinical practice
• Integration of multi-omics data platforms to understand the disease progression.
The technology has been extensively employed in diagnosis, prognosis, and therapy selection across various domains, including constitutional disorders, oncology, and infectious diseases. Concurrently, an increasing amount of well curated clinical, genetic, and genomic data is being generated by NGS, further driving the development of precision medicine. Notably, the U.S. Food and Drug Administration (FDA) has recently introduced the guidelines for the design, development, and validation of NGS tests, and approved several NGS-based tests and targeted therapies.
In addition, the Centers for Medicare & Medicaid Services (CMS) has been monitoring the rapid innovation of NGS tests, ensuring comprehensive coverage for these NGS-based tests. These remarkable advancements have significantly increased the application of NGS into clinical settings.
Therefore, this research topic aims to gather the most-up-to-date developments in NGS technologies, bioinformatics pipeline for NGS data analysis, and their clinical applications. We welcome Original Research Articles, Reviews, Mini Reviews, Systematic Reviews, Perspectives, Commentaries, Data notes, and technical notes, but are not limited to the following:
• Newly developed NGS technologies in precision medicine
• Newly developed bioinformatics pipeline/programs for NGS data analysis
• Clinical applications of NGS in diagnosis, prognosis, and therapeutics of cancers, inherited diseases, infectious diseases and chronic diseases.
• Studies bridging the gap between NGS research and clinical practice
• Integration of multi-omics data platforms to understand the disease progression.
Keywords: Next-Generation Sequencing, Clinical Genomics, Oncology, Precision Medicine, Biomarker Discovery
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
